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Abstract
U.S. military physicians and researchers have collaborated in the development of eight U.S.-licensed vaccines since 1934, when product
efficacy requirements were added to product safety requirements mandated in 1902. These vaccines include influenza (1945), rubella (1969),
adenovirus types 4 and 7 (1980), meningococcus A, C, Y, W-135 (1981), hepatitis B (1981), oral typhoid (1989), Japanese encephalitis (1992),
and hepatitis A (1995). Current efforts include new adenovirus and Japanese encephalitis vaccines, and vaccines to prevent dengue, diarrhea due
to enterotoxigenic E. coli, Campylobacter, and Shigella, malaria, hemorrhagic fever with renal syndrome, scrub typhus, meningococcus type
B, and HIV infection. All vaccines currently administered to U.S. military forces must be licensed by the U.S. Food and Drug Administration
(FDA).
Published by Elsevier Ltd.
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1. Introduction
Development of vaccines for the U.S. military has been
a priority for the U.S. Department of Defense (DoD) (and
before it the Department of War (1789–1947) and the
National Military Establishment (1947–1949)) because vac-
cines can be administered prior to deployment to protect
0264-410X/$ – see front matter. Published by Elsevier Ltd.
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service members from endemic diseases, thereby providing
protection from infection while avoiding a logistical burden
in the field. The U.S. military contributed to the develop-
ment of approximately one-half of nonpediatric vaccines that
are currently administered to service members at the time of
induction or pre-deployment.
U.S. biologic safety regulation efforts commenced in 1902
with passage of the Biologics Control Act, following the
deaths of 13 children in 1901 attributed to tetanus infections
contracted via administration of diphtheria antitoxin gener-
ated by a tetanus-infected horse. U.S. biologics regulation
was initially delegated to the Division of Pathology and Bac-
teriology within the Hygienic Laboratory of the Public Health
and Marine Hospital Service. The Hygienic Laboratory was
renamed the National Institute of Health (NIH, originally one
institute) in 1930, and vaccine efficacy requirements were
mandated in 1934. In 1937, regulatory biologics work was
delegated to a newly established Division of Biologics Con-
trol within NIH. In 1944, this division was redesignated the
Laboratory of Biologics Control, and in 1948 this division
became part of the National Microbiological Institute. In
1955 this laboratory was given separate division status within
the National Institutes of Health and renamed the Division
of Biologics Standards. In 1972, responsibility for biologics
regulation was shifted to the U.S. Food and Drug Administra-
tion (FDA), but many buildings where the biologic regulatory
work is undertaken remain to this day on the NIH campus
[1,2]. All vaccines currently administered to U.S. military
forces must be U.S. FDA-licensed.
2. Influenza virus vaccine
The first U.S.-licensed vaccine co-developed by the U.S.
military was an influenza virus vaccine. This vaccine was
developed to protect service members and civilians from
sickness and death due to influenza. During the influenza
pandemic of 1918–1919, one out of every 67 U.S. service
members died of influenza (mostly within a 10-week period
beginning in September 1918). The U.S. Army lost a greater
proportion of men to death by disease in 1918 than in any
year since 1867, when more than 43,000 U.S. sailors and
soldiers died of flu and pneumonia. Furthermore, the close
quartering and transport of large numbers of military person-
nel across oceans may have contributed to rapid global spread
of influenza [3,4].
Influenza viruses are comprised of seven to eight single-
stranded RNA gene segments. The segmented nature of the
genome permits reassortment of RNA between influenza
viruses during dual infection, thereby allowing the creation
of forms of influenza unrecognized by the human immune
system. The major reservoir for influenza A in nature is
aquatic fowl, although swine are susceptible to infection
with influenza viruses from both birds and humans and may
serve as a “mixing vessel” resulting in novel, disease-causing
strains. Influenza A and B viruses are the principal causes
of epidemic influenza, although other respiratory viruses
(including adenoviruses) can cause similar disease. Gener-
alized symptoms, including fever, chills, muscle aches, and
headaches generally precede other symptoms including sore
throat, nasal symptoms, hoarseness, cough, and diarrhea.
Death (in 0.1% of cases in most years) is generally limited to
very young and very old persons, and is frequently attributed
to pneumonia. In the 1918–1919 influenza pandemic years,
larger proportions of young adults died, sometimes follow-
ing an abbreviated course of illness marked by cyanosis and
hemorrhagic manifestations.
During World War I, U.S. Army Surgeon General William
Gorgas developed a series of commissions to gather the best
civilian and military input on ongoing and recurring infec-
tious disease problems. In the spring of 1918, a Pneumonia
Commission was formed. In 1941, the Army established the
Board for the Investigation and Control of Influenza and
Other Epidemic Diseases in the Army, which evolved into
the Army Epidemiological Board in 1944 and the Armed
Forces Epidemiological Board (AFEB) in 1949 [5]. Influenza
strains were obtained from Thomas Francis, Jr., the first
director of the Commission on Influenza, AFEB, who later
served as president of the AFEB (1958–1960) and also served
as director of the Department of Epidemiology at the Uni-
versity of Michigan’s School of Public Health. (Of note,
the live-attenuated influenza vaccine licensed in 2003 also
originated at the University of Michigan.) Francis is cred-
ited with having been the first scientist to isolate influenza
virus from a human in the United States in 1935 and also
the first to isolate influenza B. The influenza virus strains
contributed by Dr. Francis were used to make an inacti-
vated whole-virus vaccine evaluated by clinical studies in
hospitalized inmates, military recruits, and college students
[6–8]. U.S. Army troops were vaccinated against influenza
type A starting in 1943 prior to influenza vaccine licen-
sure by Parke, Davis and Company of Detroit, Michigan in
1945 because of concern that mobilization of troops could
enhance influenza transmission resulting in another serious
pandemic. A bivalent vaccine was produced adding inac-
tivated influenza type B virus starting in 1945 following
the demonstration of protective efficacy of the type B vac-
cine. The majority of U.S. Army troops were given bivalent
influenza vaccine by November 1945 per orders from the
Army Surgeon General on 10 August 1945. An increasing
incidence of influenza B was noted in the United States
during November and December 1945, but it was reported
that Army personnel who had received influenza vaccine
experienced a much lower incidence of illness than unvac-
cinated Navy and civilian groups [5]. Because the type A
vaccine failed to protect against a new “A-prime” subtype of
influenza type A in 1947, this A-prime subtype was added
to produce a trivalent inactivated vaccine. Subsequently, a
policy to change vaccine virus subtypes based on circulating
influenza strains was initiated following recognition that anti-
genic shifts impacted influenza virus transmission in humans
[9].
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The vaccine used to combat the 1957 influenza pandemic
utilized a viral strain isolated from a sick U.S. sailor returning
from a port call in Hong Kong by U.S. Army investigators sta-
tioned in Japan. The virus was sent to Maurice Hilleman (then
at the Walter Reed Army Institute of Research [WRAIR]
in Washington, DC) for characterization. Subsequently, the
virus was shared with the NIH Division of Biologics Stan-
dards, which then provided the strain to industry [10]. In
1976, an outbreak of influenza on a military post caused
by a virus similar to the causative agent of the 1918–1919
pandemic resulted in an effort to immunize the entire pop-
ulation of the United States [11–13]. Because of reports
of Guillain–Barre syndrome in civilian (but not military)
recipients of influenza vaccine, the immunization effort was
terminated [14–16].
The U.S. military has supported other studies investigat-
ing the transmission and prevention of influenza in military
populations, and components of the U.S. military con-
tinue research on influenza and influenza vaccines [17–23].
Between 1961 and 1993, the AFEB made 53 separate recom-
mendations regarding the composition of influenza vaccines.
More recently, the Assistant Secretary of Defense (Health
Affairs) has issued several policy statements per year guiding
the DoD in influenza management, and DoD representatives
often participate in the FDA advisory committee that reviews
influenza-related products.
3. Rubella vaccine
German researchers first described the disease “German
measles” – later known as “rubella” from the Latin “rubel-
lus” meaning “reddish” – as distinct from measles in 1814.
Rubella is caused by a single-stranded RNA virus that spreads
person-to-person (humans are the only known host) via res-
piratory droplets. The rubella virus causes fever and rash,
which is followed by prolonged joint pain and inflammation
in rare cases. However, in early gestation rubella infection can
result in serious fetal malformations (hearing impairments,
heart defects/inflammation, mental retardation, brain inflam-
mation, hepatomegaly, splenomegaly, and thrombocytopenia
[24]).
Prior to 1969, U.S. military recruits and military hospi-
tal workers (particularly women of childbearing age) were at
risk for rubella infection and sequelae. Beginning in 1947,
pregnant women exposed to rubella were given convalescent
serum or immune serum globulin to prevent fetal infection. A
rubella pandemic that hit Europe in 1962 and then caused 12.5
million cases of rubella and 2000 cases of rubella encephalitis
in the United States from 1963–1964, with 30,000 afflicted
infants (1% of all pregnancies, with 6250 spontaneous abor-
tions and 2100 excess neonatal deaths) prompted rubella
vaccine efforts.
In 1961, Lieutenant Colonel (LTC) Edward Buescher, U.S.
Army Captain (CPT) Malcolm Artenstein, and CPT Paul
Parkman of WRAIR isolated the rubella virus from a recruit
hospitalized at Fort Dix during an adenovirus outbreak inves-
tigation after noting interference with enteroviral growth in
African green monkey kidney cell cultures—a technique pio-
neered by scientists at WRAIR. (Thomas Weller and Franklin
Neva also isolated the rubella virus at Harvard University in
1962.) Parkman then moved on to the Division of Biolog-
ics Standards at NIH, where, together with Harry Meyer, he
used the isolated HPV-77 virus grown in duck-embryo culture
to create Meruvax (Merck)—a live-attenuated viral vaccine
manufactured by Merck Sharp & Dohme that was one of
three rubella vaccines licensed in the United States in 1969
(a different viral strain [RA 27/3] was used as the basis of
Meruvax II beginning in 1979 [25,26]).
The impact of rubella vaccine has been dramatic. During
the 3 years before vaccines were brought to market in 1969,
47,745 cases of rubella were recorded in the United States. As
of 2005, the U.S. Centers for Disease Control and Prevention
announced that rubella virus infection was no longer endemic
in the United States [27].
4. Adenovirus vaccines (types 4 and 7) and related
research efforts
Acute respiratory disease (ARD) caused by a variety of
pathogens has been a long-standing important cause of mor-
bidity and sometimes mortality among military personnel
(particularly recruits), attributed in part to crowded living
conditions and physical stress. Adenovirus – a frequent cause
of epidemic ARD associated with pneumonia, hospitaliza-
tions, and some deaths – is a proven threat to military
readiness and also causes illness among civilians [26,28].
Adenoviruses are DNA viruses that are usually transmitted
via respiratory (aggravated by crowding) or ocular (related
to lack of hand washing) routes. Asymptomatic infection
and a prolonged carrier state contribute to spread. Diseases
associated with adenoviral infections include febrile res-
piratory illness (bronchitis or pneumonia), eye infections
(conjunctivitis), pharyngitis, and diarrhea. Complications of
adenovirus include acute otitis media, pneumonic infections,
and death. There is no effective antiviral treatment for aden-
ovirus at the present time.
During World War II, epidemics of respiratory disease in
recruits disrupted training and greatly increased the burden
on medical staff and facilities. A commission on ARD was
established at Fort Bragg in North Carolina from 1942 to
1945 to undertake epidemiological studies. The viral nature
of these infections was established when bacteria-free fil-
trates were shown to transmit the infection to volunteers. The
impact of ARD on recruits undergoing Basic Combat Train-
ing (BCT) was assessed in prospective studies in the 1950s,
when Maurice Hilleman and his co-workers established that
20% of recruits were hospitalized with febrile ARD, another
20% sought evaluation at an outpatient facility, 40% had mild
or inapparent infections, and the remaining 20% (probably
immune) were not infected. In a similar subsequent study
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of an ARD outbreak in recruits at Fort Dix in the 1960s,
Buescher and his co-workers observed that 37% were hospi-
talized with febrile ARD and an additional 48% were also ill
with less severe infections.
In the course of investigating an influenza epidemic at Fort
Leonard Wood in 1952–1953, Hilleman and J.H. Werner at
WRAIR identified adenovirus types 4 and 7, which cause
the vast majority of clinically apparent adenovirus infections
afflicting unvaccinated recruits during BCT, and established
the importance of neutralizing antibody as a marker of
immunity for these infections [29,30]. Before vaccines were
available, adenovirus was consistently isolated in 30–70%
of trainees with ARD, and adenoviruses were associated
with 90% of the cases of pneumonia among trainees in BCT
[31,32].
Effective formalin-inactivated parenteral types 4 and 7
vaccines were licensed by the FDA in 1956, but the license
was revoked in 1963 because of manufacturing problems
including variable potency and concerns regarding poten-
tial oncogenicity due to contamination with SV-40 [33].
Because ARD epidemics caused by adenovirus types 4 and
7 continued, R.M. Chanock, W.P. Edmondson, F.H. Top, Jr.,
and co-workers at WRAIR developed highly antigenic live
oral adenovirus types 4 and 7 vaccines. These oral types
4 and 7 adenovirus vaccines were effective in decreasing
cases of ARD resulting in hospitalization of recruits by 50%
without producing adverse effects and were approved by
the FDA for distribution by Wyeth Laboratories in 1980
[34–37].
In 1995, Wyeth – the sole manufacturer of adenovirus
vaccines – ceased production of these vaccines when faced
with an FDA requirement for costly updated manufacturing
facilities for the vaccine. DoD supplies of adenovirus type 4
vaccine and adenovirus type 7 vaccine were depleted by 1998
and 1999, respectively. Since termination of Wyeth vaccine
production, the burden of adenovirus disease in recruits has
increased to that of the pre-vaccine era. Further, a study found
that nearly 90% of new recruits were seronegative for either
type 4 or 7 adenovirus, and therefore susceptible to aden-
ovirus infection [38,39]. Because of the surge of adenovirus
cases, the DoD contracted with Barr Laboratories (now Barr
Pharmaceuticals) in September 2001 to develop replacement
live types 4 and 7 adenovirus vaccines. The first clinical study
of the new adenovirus vaccines has been successfully com-
pleted by investigators at Fort Sam Houston, and a Phase 3
trial commenced in September 2006.
5. Meningococcal vaccines
Neisseria meningitidis, the causative agent of meningo-
coccal meningitis, is a Gram-negative bacterium with the
microscopic appearance of two kidney beans aligned along
their long axis. The bacteria are encapsulated by a polysac-
charide coat, which contains an important determinant
of potential virulence. Five antigenically distinct capsular
polysaccharide serogroups, designated groups A–C, Y, and
W-135, account for almost all human disease, although 13
groups have been identified.
The bacteria are transmitted via infected respiratory
droplets under conditions favoring close person-to-person
contact. Humans serve as the only host and reservoir for N.
meningitidis infections. Meningococcal bacteria may either
harmlessly colonize the human nasopharynx or become
invasive pathogens causing bacterial sepsis and meningitis.
Invasive meningococcal infections cause significant mor-
bidity (sudden fever, headache, nausea, rash, delirium, and
coma) and rapid mortality (the case–fatality ratio for all inva-
sive meningococcal disease is estimated to be 11%) [40].
Whether a given meningococcal infection will result in an
asymptomatic carrier state or in a devastating systemic dis-
ease depends on host immunity, bacterial virulence, and other
factors (lack of a spleen, cigarette smoking, viral upper res-
piratory infections, and alcohol consumption are associated
with increased risk of disease).
Infections with N. meningitidis bacteria occur globally.
Large-scale epidemics afflict Africa (particularly in the sub-
Saharan region) during the dry season. As is the case
with adenovirus infections, increased risks of meningococ-
cal infections are associated with close exposures to large
groups of people from diverse locales who are under stress.
The risk of meningococcal disease transmission to pilgrims
to the Islamic holy city of Mecca in Saudi Arabia (and to
subsequent contacts of the pilgrims) has been recognized for
decades. The highest incidence of bacterial meningitis occurs
in children under the age of 5 years, but there is a second peak
in disease incidence among teenagers and young adults.
Outbreaks of meningococcal disease among military
recruits and soldiers have been documented since the nine-
teenth century, although the etiology was not recognized until
later. Epidemic disease erupted among U.S. troops during
World War I. Because a similar experience was predicted
with the U.S. entry into World War II, the Army’s newly
formed epidemic diseases board created a Commission on
Meningococcal Meningitis (1941–1946) to accelerate sci-
entific study of the disease. The commission documented
more than 5000 domestic cases among U.S. Army personnel
occurring between 1941 and 1943, mostly in soldiers dur-
ing the first 3 months of military service. During the period
from 1964 to 1971, coincident with the Vietnam War, an epi-
demic of groups B and C meningococcal disease occurred in
U.S. military basic training centers, resulting in temporary
closing of Fort Ord in California. Approximately 2400 cases
occurred in active duty military personnel with a case–fatality
ratio of about 7.2% (about 170 deaths). During the Viet-
nam War, there were at least as many deaths among U.S.
military personnel attributed to meningococcal disease as
were attributed to malaria. This epidemic and the high rate
of emergence of meningococcal strains resistant to prophy-
lactic antimicrobials led to an intensive effort at WRAIR
to develop vaccines to protect military service members
[41].
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Beginning in 1963, a team of investigators, led by Mal-
colm Artenstein, Emil Gotschlich, and Irving Goldschneider
conducted studies over a 5-year period that elucidated the
human immunological response to meningococcus and pro-
vided a basis for the successful development of effective
polysaccharide vaccines for serogroups A and C [42–48].
The concept of using polysaccharides as immunogens was
an outgrowth of work on pneumococci performed at the
Rockefeller Institute in the 1930s and 1940s that led to a
successful trial of a tetravalent pneumococcal polysaccharide
vaccine among military personnel in 1945 [5]. The WRAIR
team’s contributions included development of methods for
purification of high molecular weight polysaccharides from
groups A–C; physical and chemical analysis of the polysac-
charides; and immunogenicity studies in several animal
species.
WRAIR scientists created the first subunit vaccine
designed to prevent type C infections and completed Phase
1–3 clinical trials involving production of clinical grade
vaccine that demonstrated safety and high efficacy and cul-
minated in the licensure of the vaccine. The Phase 3 trials
required a large sample size and multiple locations given
the relatively low incidence of meningococcal disease, the
lack of exact predictability of the location of an outbreak,
and the impact of vaccinated persons on illness transmission
(herd effect). Such trials also required careful organization,
because informed consent and vaccinations in new recruits
had to be accomplished within days of arrival before acquisi-
tion of the carrier state. In the first efficacy study, 13,763 men
at five different military posts were vaccinated with a group
C polysaccharide vaccine, and more than 53,000 men served
as unimmunized control subjects. The vaccine safely reduced
the acquisition rate of group C meningococci (although not
that of other meningococcal groups) and the rate of systemic
meningococcal disease caused by group C organisms dur-
ing an 8-week period [47]. A second large field trial yielded
similar results [48].
This meningococcus polysaccharide C vaccine began to be
used for routine vaccination of recruits entering basic train-
ing in 1970 and was replaced by an A/C divalent vaccine in
1978. Work on the development of vaccines for serogroups
Y and W-135 and testing of a tetravalent A, C, Y, W-135 vac-
cine took place independently at several institutions including
Connaught Laboratories, WRAIR, Institut Me´rieux, and the
Rixensart, Belgium branch of Smith Kline between 1975 and
1981. The groups Y and W-135 capsular polysaccharides
were purified and characterized by these different institutions
using the same methods developed at WRAIR for the groups
C and A vaccines [49,50]. Connaught Laboratories’ purified
capsular polysaccharide A, C, Y, W-135 tetravalent vaccine
(commercial name: Menomune), licensed by the FDA in
November 1981, was based on the company’s own clinical
data. A tetravalent meningococcal vaccine is indicated for
military recruits, persons lacking spleens, individuals with
terminal complement deficiencies, travelers to areas where
meningococcal disease is hyperendemic or epidemic, and
subgroups of college students [51–54]. A protein-conjugated
tetravalent meningococcal vaccine (Menactra) was licensed
to Aventis Pasteur by the FDA on 14 January 2005, and
should be of particular value to young children, for whom
polysaccharides are poorly immunogenic, but will also be
used henceforth by the U.S. military [55].
A group B meningococcal vaccine has been under devel-
opment at WRAIR since 1969. Since the epidemic in the
1960s, group B disease has remained at a relatively low level
with occasional small clusters of cases occurring at differ-
ent training posts. However, group B meningococcal disease
remains a threat for the U.S. military, in part because the rapid
onset of severe, potentially fatal disease and risk of transmis-
sion to close contacts result in a high level of concern and
disruption to normal operations. Group B N. meningitidis
is currently responsible for about 25–90% of all meningo-
coccal disease in North and South America and in most
European countries. Over the past 25 years, group B epi-
demics have occurred in Norway, Cuba, Chile, Brazil, and
New Zealand. Many of these epidemics have been caused by
a single genetic clone known as ET-5, which is particularly
virulent and first appeared in Norway in the 1970s. Devel-
opment of a vaccine against serogroup B – a much more
difficult task compared to development of a vaccine for the
other meningococcal serogroups due to antigenic similarity
between the group B strain capsule and components of human
nerve cells – requires identification of a stable immunogenic
antigen common to all serogroup B meningococci or formu-
lation of a multivalent vaccine providing protection against
a large portion of group B antigenic variants. This effort has
been slowed by the antigenic variation and/or phase vari-
ation associated with most of the antigens that have been
demonstrated to induce bactericidal antibodies and by the
lack of a good animal model for the disease. Nevertheless,
research on potential antigens created from native outer mem-
brane vesicles (NOMV) and detoxified lipooligosaccharides
(dLOS) continues. A series of candidates have been evaluated
in humans [56–59].
6. Hepatitis B vaccine
Hepatitis B virus (HBV) is transmitted by blood-to-blood
and sexual contact and is an important cause of acute and
chronic hepatitis in many countries. The clinical features of
acute hepatitis B infection resemble those caused by other
hepatitis viruses. The HBV virus persists in approximately
5–10% of healthy adults, and in as many as 90% of infants
infected at birth. Persistent carriage of hepatitis B, defined
as the presence of hepatitis B surface antigen (HBsAg) in
serum for more than 6 months, has been estimated to affect
about 350 million people worldwide, although not all carriers
can transmit the virus to others. Long-term continuing HBV
replication can result in chronic liver disease, cirrhosis, and
hepatocellular carcinoma, and results in 1–2 million deaths
per year. Primary liver cancer is among the 10 most common
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cancers worldwide, and currently 80% of such cancers are
ascribed to persistent infection with HBV.
Soldiers are at risk for exposure to HBV via contaminated
blood and body fluids during battle and sexual intercourse.
Acute hepatitis was one of the main causes of illness among
military personnel during the Vietnam War. A significant part
of this was probably a consequence of contaminated needle
use. Some service members from Vietnam and other wars
continued injected drug use after returning to the United
States and remained at risk from hepatitis B from shared
needles.
The U.S. military became focused on hepatitis B after
the summer of 1942, when 50,000 cases of jaundice and 62
deaths occurred among soldiers vaccinated with yellow fever
vaccine [60,61]. Investigators attributed the illness to a virus
transmitted from human serum used in vaccine manufacture
[62]. The epidemic ceased after suspect vaccine lots were
destroyed, and a human serum-free process whose develop-
ment was led by U.S. Public Health Service officer Mason
V. Hargett was utilized [63]. Investigations of stored samples
many years later confirmed that the causative agent was HBV.
Beginning in 1944 and continuing through the 1970s,
the U.S. Army Surgeon General’s office supported studies
at Yale University and the Willowbrook State Hospital in
New York that characterized the epidemiology and required
immunoprophylaxis for two different viral causes of epi-
demic hepatitis, including hepatitis B. Following Baruch
Blumberg’s discovery of the Australia antigen (HAA, now
known as HBsAg) in 1965, the association of this antigen with
hepatitis B was recognized, which made possible additional
epidemiological studies linking hepatitis B with intravenous
drug abuse and sexual exposure.
In the late 1960s, scientists at the U.S. Army Medical
Research Laboratory at Fort Knox, Kentucky collaborated
in a study of more than 1600 service members; the cohort
included both soldiers who had recently returned from Viet-
nam and recruits who had not yet been to Southeast Asia. A
significantly higher frequency of HBsAg carriers was noted
among the returnees (about 0.7%) than among the recruits
(0.2%). In the early 1970s, a second larger study involv-
ing nearly 20,000 Vietnam War returnees and recruits was
initiated that also incorporated data from returnees partici-
pating in a drug rehabilitation program. The higher HBsAg
rate among newly returned service members was attributed
to HBV acquired via injected drug use, but some returnees
initially testing positive eventually became HBsAg negative
due to presumed recovery from HBV [64,65].
These studies sponsored by the U.S. military helped doc-
ument the need for a hepatitis B vaccine. The first-generation
hepatitis B virus (HBV) vaccine (Heptavax B, which was
licensed by the FDA to Merck Sharp & Dohme in 1981)
was prepared from 22-nm HBsAg particles purified from
plasma donations from chronic HBV carriers [66]. These
preparations (not tested by the U.S. military) are safe and
immunogenic, but have been replaced in most countries by
recombinant vaccines produced by the expression of recom-
binant HBsAg in yeast cells. Current HBV vaccines utilize
subtype “adw.” Investigators at WRAIR carried out early
work on subtyping strains of HBsAg from different geo-
graphic regions and first described the “w” and “r” antigenic
determinants [67]. While working at the Southeast Asia
Treaty Organization (SEATO) Medical Research Labora-
tory in Thailand (which became the Armed Forces Research
Institute of Medical Sciences [AFRIMS] in 1977), William
Bancroft found that saliva from humans with chronic hepatitis
B contained infectious HBV [68].
7. Typhoid vaccine (oral live typhoid Ty21a vaccine)
Typhoid fever, an acute generalized illness primarily strik-
ing adolescents and young adults caused by infection with
the bacterium Salmonella typhi, is characterized by fever,
headache, abdominal pain, mild erythematous macular rash
(“rose spots”), and bowel movement and mental changes. The
word “typhoid” is derived from the Greek “typhos” (deliri-
ous) because the disease is associated with mental confusion.
S. typhi, which causes infection only in humans, is acquired
by ingestion of contaminated food or water or finger-to-
mouth contact with contaminated feces. The infection can
be spread by a healthy carrier of the bacterium (“Typhoid
Mary”), a person ill with the disease, or contaminated flies.
Major complications include gastrointestinal hemorrhage,
bowel infarction with peritonitis, pericarditis, meningitis, and
septic arthritis, and the disease may be fatal in untreated
susceptible persons.
During the Spanish-American War, one-fifth of U.S.
troops (mostly U.S. Army personnel) had typhoid fever, and
over 1500 persons died of the disease; some acquired the
infection in U.S. training camps before going overseas. In the
Anglo-Boer War, the British army lost more men to typhoid
(8225 deaths) than it did to wounds (7582 deaths). Develop-
ment of a typhoid vaccine became a priority for both nations
[69].
Observational studies dating back to the Civil War (when
44,558 Union soldiers died of diarrhea or dysentery com-
pared with 110,070 combat-related deaths) revealed that
some typhoid fever survivors were not susceptible to repeat
bouts of this illness [70]. This evidence of natural immu-
nity prompted efforts to develop vaccines to prevent typhoid
fever. The first typhoid vaccines were created in Britain in
1896 by Sir Almroth Wright. After Major (MAJ) Freder-
ick Russell of the U.S. Army modified this vaccine to create
a subcutaneous form and conducted studies in volunteers
demonstrating safety and efficacy, typhoid immunization was
required of U.S. service members beginning on 30 Septem-
ber 1911 [71]. Typhoid vaccine was licensed in the United
States in 1914. This vaccine prevented outbreaks of typhoid
fever in U.S. Army troops dispatched to the U.S.-Mexican
border because of the Mexican revolution. The U.S. Army
became the first military organization in the world to make
typhoid vaccination mandatory and had the lowest typhoid
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fever incidence of any major combatant in World War I. Fur-
thermore, despite the relatively low efficacy of all typhoid
vaccines used in highly endemic areas in comparison to other
vaccines co-developed by the DoD, no major typhoid out-
breaks have impacted deployed U.S. forces in subsequent
wars [72–74].
Advances in microbiology have led to a dramatic reduc-
tion in the number of cases of severe diarrhea in the developed
world, but typhoid fever and other diarrheal illnesses remain
an important problem in countries that lack clean water
and well-functioning sanitation systems. Because typhoid
remains a threat to U.S. troops deployed to such areas, and
early typhoid vaccines were associated with some adverse
effects, newer vaccines have been created. The U.S. military
contributed to the development of the more recently licensed
oral typhoid vaccine. M.M. Levine and others conducted
large-scale DoD-funded studies in the 1980s in collaboration
with the Chilean Ministry of Health that demonstrated 67%
efficacy of an enteric-coated vaccine based on an attenuated
Ty21a strain of S. typhi in conditions of moderate typhoid
fever transmission in Chile [75–77]. Later that decade, C.H.
Simanjuntak and others at the U.S. Naval Medical Research
Unit No. 2 (NAMRU-2) in Jakarta and the Indonesian Min-
istry of Health demonstrated 42% efficacy of this vaccine in
a setting of intense transmission of typhoid fever in Jakarta
[78]. Berna Products (now Acambis) was granted licensure
by the FDA in December 1989 for the attenuated live oral
enteric-coated vaccine based on Ty21a. As is the case with
all typhoid vaccines, whether given by mouth or injection,
recipients are also advised to take other preventive measures
against typhoid, such as practicing good hygiene.
The U.S. military has contributed to control of typhoid
fever in other ways: (1) Identification of pathological bowel
findings (such as enlarged intestinal lymphoid follicles or
“Peyer’s patches”) during autopsies by U.S. Civil War sur-
geons were eventually linked to typhoid infection. (2) In
1899, during the Spanish-American War, the Reed-Vaughan-
Shakespeare Typhoid Board was established. This board,
with MAJ Walter Reed, MAJ Victor C. Vaughan, and MAJ
Edward O. Shakespeare, carried out epidemiological inves-
tigations focusing on typhoid fever and noted that the U.S.
Army had failed to undertake established sanitary measures
to prevent typhoid fever during the Spanish-American War.
Another important observation of the Typhoid Board was that
either sick or healthy human carriers of typhoid bacilli were
important sources of typhoid infection. (3) MAJ Carl Dar-
nall developed a method of water purification in 1910, and
MAJ William Lyster developed a water purification system
using calcium hypochlorite in a linen bag (Lyster bag) in
1915. These techniques have improved the safety of water
supplies for both military personnel and civilians around the
world.
The U.S. military has also contributed to improved treat-
ments for typhoid fever patients. In 1948, Joseph Smadel,
Theodore Woodward, Herb Ley, and Charles Wissman of
WRAIR noted that a patient given chloramphenicol for
scrub typhus had typhoid fever responsive to chloram-
phenicol [79]. Subsequently, investigators at NAMRU-2
(Jakarta, Indonesia) and NAMRU-3 (Cairo, Egypt) have
demonstrated the utility of other antimicrobial agents
such as ciprofloxacin, azithromycin, and third-generation
cephalosporins for typhoid fever [80–83]. In 1984, Stephen
Hoffman and others revealed the usefulness of the corti-
costeroid dexamethasone in reducing mortality from severe
typhoid fever [84]. In the 1960s, CPT Robert Phillips devel-
oped intravenous and oral rehydration techniques useful in
preventing dehydration caused by all forms of severe infec-
tious diarrhea that are estimated to have saved many millions
of lives [85].
8. Japanese encephalitis vaccine and current related
research
Japanese encephalitis virus (JEV; previously called
Japanese encephalitis type B) is a flavivirus transmitted by
mosquitoes that is associated with outbreaks of encephalitis
in Asia, the Pacific Islands, Northern Australia, and Russia.
JEV transmission is generally seasonal and limited to rural
areas (pigs and birds are important for viral maintenance,
amplification, and spread). Within Asia, Japanese encephali-
tis (JE) is the most important cause of human encephalitis
and causes approximately 35,000 cases and 10,000 deaths
annually. Although between 25 and 1000 asymptomatic JEV
infections occur for each identified clinical case of JE, and
symptoms may be limited to mild illness with fever in some
persons, the case–fatality ratio for persons with evident dis-
ease is about 25%, and at least 50% of JE survivors have
sequelae ranging from mood changes to severe neurological
impairment [86]. Currently, there is no effective treatment of
JE beyond supportive care. Use of pesticides results in minor
reductions of JEV vectors in a limited area for a short period
of time at considerable cost.
JEV was first isolated in 1935 from the brain of a patient
dying of encephalitis in Japan. At the beginning of World
War II, anticipating possible epidemics among U.S. forces
in the Pacific, the Commission on Neurotropic Virus Dis-
eases of the Army Epidemiological Board assigned MAJ
Albert Sabin the task of developing a vaccine against JE.
A crude vaccine derived from formalin-inactivated brains of
mice infected with JEV was developed (based on the earlier
work of Japanese and Russian scientists) and administered to
approximately 250,000 military personnel during World War
II, beginning shortly after a 1945 JE outbreak among U.S.
troops in Okinawa. In addition, Sabin and others recorded
clinical descriptions of laboratory-confirmed cases and per-
formed studies to identify the natural vectors and reservoirs
of the virus.
The need for a more efficacious vaccine became appar-
ent during U.S. involvement in the Korean War, when there
were 299 cases of proven or suspected JE among U.S. forces
despite administration of JE vaccine to all U.S. troops in the
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Far East Command between 1946 and 1951 (at which point
the U.S. Army ceased JE vaccine administration).
The ecology of JEV was elucidated in greater detail by
WRAIR investigators Buescher and Scherer working in Japan
in the late 1950s [87]. Increased demand for a JEV vaccine
for U.S. civilians began in 1981, when a 20-year-old student
from Washington, DC contracted fatal JE while attending
Beijing University. Japanese encephalitis vaccine trials were
conducted in the United States by the U.S. Centers for Disease
Control (CDC) beginning in 1983 under Investigational New
Drug Application authorization from the FDA.
In the mid-1980s, a DoD team led by Charles Hoke with
collaborators in the Thai Ministry of Public Health conducted
the definitive study evaluating two doses (given 1 week
apart) of the highly purified BIKEN vaccine (Nakayama-
Yoken strain) versus a bivalent vaccine (Nakayama-Yoken
and Beijing-1 strains) versus placebo (tetanus toxoid). There
were approximately 22,000 Thai schoolchildren in each of
these recipient groups. The efficacy of both monovalent and
bivalent vaccines was 91%, achieved with minor vaccine
adverse effects (headache, sore arm, rash, and swelling), and
these data [88–91] were pivotal in obtaining FDA licensure
of JE-VAX – a formalin-inactivated whole virus vaccine –
on 10 December 1992. This large clinical trial was facili-
tated by (1) development of a new IgM test by Donald Burke
at AFRIMS and (2) the comprehensive placebo-controlled
study of the BIKEN vaccine in volunteers in the 25th Infantry
Division in Hawaii, which demonstrated that the vaccine was
safe and antibody levels persisted 3 years after immunization
[88,92,93]. This is currently the only FDA-licensed vaccine
for Japanese encephalitis. The manufacturing company was
the Research Foundation for Microbial Diseases of Osaka
University (BIKEN), and the vaccine was distributed in the
United States by Sanofi Pasteur. An initial three-dose regi-
men (plus booster doses) is recommended by the CDC for
optimal immune response.
BIKEN/Sanofi Pasteur discontinued production of JE-
VAX in 2005 in part because of concern about (non-life-
threatening) adverse vaccine effects. Because it is anticipated
that the entire DoD stockpile of available JE-VAX will have
been expended by the 2008 fiscal year following utilization
by Navy personnel and Marines deployed to Asia, WRAIR
and other U.S. military laboratories have collaborated with
a commercial partner (Intercell) to test a second-generation
formalin-inactivated Vero cell culture-based JEV vaccine for-
mulated with alum.
9. Hepatitis A vaccine
Hepatitis A virus (HAV) – a non-enveloped, single-
stranded RNA virus – is endemic worldwide, although rates
of transmission vary depending on national income level (a
surrogate for sanitary infrastructure). The virus is transmit-
ted when food or water becomes contaminated with feces
of infected persons. In developing nations, the virus is gener-
ally acquired early in life and rarely causes severe symptoms.
In developed nations with better sanitation, infection with
hepatitis A may be delayed until an individual travels to an
underdeveloped area or there is an unusual breakdown in san-
itation. Infections in adults may be associated with serious
symptoms and rare fatalities.
Epidemics of hepatitis A have repeatedly afflicted the
U.S. military during deployments to regions with subopti-
mal sanitation, water, and waste systems. During the Civil
War, epidemic hepatitis (most likely due to hepatitis A virus)
was common, but few deaths were recorded. During the sec-
ond year of the war, about 50 of every 1000 men became
jaundiced; only about half this number were diagnosed in
subsequent years of the war. Although improved sanitation
may have contributed slightly to the decrease, it is more likely
that veteran soldiers were eventually exposed to the disease
and acquired immunity [94]. In World War I, hepatitis was a
serious problem for British, French, and German troops, but
less of a problem for U.S. troops. U.S. forces experienced
greater than 180,000 cases of infectious hepatitis in World
War II, with 106,695 inpatient admissions and a case–fatality
ratio of 0.3%. The annual admission rate per 1000 was 4.37
overall, with the highest rates of disease in the southwest
Pacific and the Mediterranean. During the Korean War, out-
breaks of hepatitis occurred in 1950 and 1951 related to poor
sanitation during intense conflicts, and more than 4000 troops
with hepatitis were hospitalized or restricted to quarters.
Outbreaks of hepatitis A disease have affected the military
during peacetime. In 1959, uncooked fish was implicated in
an outbreak in Naples involving 156 persons on 14 ships.
In 1974, a food handler was suspected of causing a large
number of cases (47/1000 attack rate) in San Diego. In 1980,
child care centers were recognized as a focus for hepatitis A
transmission on military posts.
In 1945, the U.S. military played a role in demonstrating
that passive immunization with immune globulin (IG) from
pooled human plasma could prevent or attenuate hepatitis A
disease [95]. A randomized, double-blind study involving
107,803 U.S. soldiers, led by COL Marcel Conrad dur-
ing the Korean War, showed that service members given
5–10 ml IG containing antibodies to hepatitis A and B by
intramuscular injection on arrival in Korea were protected
from icteric hepatitis caused by hepatitis A, hepatitis B, and
non-A, non-B hepatitis for 6 months [96,97]. This research
supported the concept that vaccines that elicited appropri-
ate antibody responses could provide protection against viral
hepatitis. However, immune globulin, which was used for
a time to protect soldiers and civilian travelers from infec-
tion with hepatitis A, requires repeated injections and is not
readily available at present. Also, with large and lengthy
deployments, distribution of IG has proved impractical and
unpopular in the military [26].
Much of the development of the FDA-licensed inactivated
hepatitis A vaccine Havrix is attributable to the U.S. military
in partnership with NIH and SmithKline Beecham (SKB, now
GlaxoSmithKline). Techniques to quantify hepatitis A virus
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and associated antibodies were developed at WRAIR. At
WRAIR and NIH (laboratory of Robert Purcell), numerous
cell types were evaluated for their ability to support growth
of hepatitis A virus, and optimal growth parameters were
defined. Both guinea pigs and monkeys developed excellent
titers of neutralizing antibody following immunization with a
prototype formalin-inactivated vaccine created by L.N. Binn,
D.R. Dubois, and K.H. Eckels [98,99]. Analysis of strains
from international sources showed antigenic similarity and
indicated that a vaccine need contain only a single serotype to
provide global protection against HAV. Human trials began at
WRAIR in 1986 with formalin-inactivated vaccine; all eight
volunteers developed neutralizing antibody after four small
doses of vaccine antigen. The DoD established cooperative
agreements with SKB for hepatitis A vaccine development
in 1989. Initial small-scale collaborative investigations
evaluated antibody responses in humans following immu-
nization with two candidate vaccine strains. A 1991 study
of coadministration of hepatitis A vaccine with hepatitis B
vaccine to soldiers found no immune interference between
vaccines. This finding eventually resulted in another 1991
study showing that accelerated hepatitis A immunization
schedules were effective for service members. A large-scale
field efficacy trial of hepatitis A vaccine (showing 94%
efficacy) was begun in 1991 (led by LTC Bruce Innis) as a
collaborative project of the U.S. Army, Thailand’s Ministry
of Public Health, and SmithKline Beecham Biologicals. In
this trial, approximately 20,000 volunteers received hepatitis
A vaccine and 20,000 received a control vaccine (hepatitis
B vaccine). Havrix, the inactivated hepatitis A viral vaccine
manufactured by GlaxoSmithKline, was licensed by the
FDA in February 1995 [65,100]. Two doses administered
6 months apart are believed to confer lifetime immunity.
The DoD was not directly involved in the licensing of
Vaqta, a second inactivated hepatitis A vaccine, by Merck in
1996.
The DoD also supported Phase 1 and 2 studies of a
recombinant hepatitis E virus (HEV) vaccine. HEV – a non-
enveloped, single-stranded positive sense RNA virus – is
transmitted via the fecal-oral route and causes acute disease
in developing countries (particularly in Africa and Asia) both
sporadically and in epidemics, causing considerable morbid-
ity and mortality, especially in pregnant women. A three-dose
recombinant protein HEV vaccine study involving collabora-
tion between the U.S. military, NIH, GlaxoSmithKline, and
the Royal Nepalese Army revealed 95.5% vaccine efficacy
without notable adverse effects [101].
10. Other past U.S. DoD-related vaccine efforts
Development of other licensed vaccines was supervised
by investigators who began their careers at military research
centers. For example, yellow fever vaccine development was
spearheaded by former Army Surgeon General William Gor-
gas while employed at the Rockefeller Foundation, and this
effort was supported by active members of the U.S. mili-
tary. Gorgas previously directed the vector control programs
that eliminated yellow fever in the Panama Canal area during
the canal’s construction. Maurice Hilleman, who is credited
with the codiscovery of adenoviruses and important influenza
research while working as a civilian at WRAIR, also played
a key role in the development of mumps, measles, varicella,
and other vaccines after joining Merck. Oral polio vaccine
was developed by Albert Sabin, who worked on influenza
and Japanese encephalitis vaccines prior to retirement from
the U.S. Army.
Also, the U.S. military contributed to the early work
for two vaccines later taken on by other investigators. The
first clinical trial of multivalent pneumococcal polysaccha-
ride vaccine – largely based on Michael Heidelberger’s work
at the Rockefeller Institute in the early 1940s – was con-
ducted at the U.S. Army Air Base in Sioux Falls, South
Dakota under the direction of the U.S. Army Epidemiological
Board’s Commission on Pneumonia. Administration of this
vaccine was associated with reduced incidence of pneumo-
nia and pneumococcal carrier rates. These important findings
did not immediately result in a commercially successful
vaccine (a 14-valent pneumococcal vaccine licensed in the
United States available from E.R. Squibb from 1947 to 1954
was an economic failure because physicians preferred to use
newly available penicillin to treat pneumococcus infections
rather than rely on a prophylactic vaccine) [26]. However,
the demonstration of a polysaccharide pneumococcal vaccine
enticed researchers to investigate polysaccharide approaches
for development of meningococcal vaccines.
Interest in the pneumococcal vaccine was revived in
1963 when Robert Austrian, professor of medicine at
the University of New York Downstate Medical Center
and later professor of research medicine at the Univer-
sity of Pennsylvania, documented the continuing importance
of pneumococcal bacteremia in South African miners. A
protein-conjugated seven-valent form of the vaccine capa-
ble of eliciting immunity in young children was licensed by
the FDA to Wyeth-Lederle in 2000. The growing problem
of antimicrobial-resistant pneumococci and development of
a protein-conjugated pneumococcal vaccine for children has
resulted in more widespread use of pneumococcal vaccines.
Since 1945, the U.S. military has been a leader in the
development of vaccines to prevent diseases caused by rick-
ettsiae and related bacterial pathogens, including epidemic
typhus and scrub typhus. Because louse-borne typhus had
caused devastating epidemics (mostly afflicting civilians and
soldiers in Eastern Europe and Russia) during and immedi-
ately after World War I, U.S. military officers and U.S. Public
Health Service officials traveled to Canada shortly after the
Japanese attack on Pearl Harbor to assess rickettsial vaccine
progress at Connaught Laboratories. The Division of Biolog-
ics Control licensed a new vaccine for louse-borne typhus in
1941 which was administered to U.S. personnel deployed to
southern Europe and North Africa. This was the first rick-
ettsial vaccine; it was produced by growing the bacteria in
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fertilized hen’s eggs (chick embryo), which was a new tech-
nique at the time. Only 64 louse-borne typhus cases occurred
among U.S. military personnel in World War II [102,103].
The U.S. military is currently attempting to develop a
scrub typhus vaccine that protects deployed service members
from a variety of strains of Orientia tsutsugamushi (previ-
ously referred to as Rickettsia tsutsugamushi). The infection,
which can cause high fever with a long convalescence or
death, is prevalent in Asia, Australia, and many Pacific islands
and is transmitted to humans via the bite of infected chiggers
(larval mites of the Trombiculidae family). Scrub typhus hin-
dered U.S. and allied troop strength during World War II
and the Vietnam War, and outbreaks occurred among U.S.
Marines training in Japan in 2000 and 2001. Evaluation of
recombinant protein and plasmid DNA scrub typhus vaccine
candidates in a chigger challenge mouse model is under way
[104].
First Lieutenant (1LT) Bailey K. Ashford proved in 1899
that Ancyclostoma duodenale, a species of hookworm, was
a key cause of anemia in Puerto Rico. His discovery led to
global therapeutic campaigns [26] and eventually to current
hookworm vaccine efforts (a Phase 1 trial conducted by the
George Washington University Medical Center in Washing-
ton, DC is under way [105]).
11. Other ongoing U.S. DoD-related vaccine efforts
Vaccines to protect against malaria, dengue, bacteria-
caused diarrhea, hemorrhagic fever with renal syndrome, and
human immunodeficiency virus (HIV) are in technology base
development (managed by the Military Infectious Diseases
Research Program [MIDRP]).
Development of vaccines to prevent and treat P. falci-
parum malaria (which may cause acute potentially fatal
disease in persons without hard-won immunity acquired from
recurrent exposure to malaria) and P. vivax malaria (most
common cause of relapsing disease) is a U.S. military pri-
ority for several reasons. Infection transmitted by female
Anopheles mosquitoes can render military personnel unable
to fight and cause life-threatening disease. Insect repellents,
bednets, and antimalarial drugs do not guarantee protection
and may have adverse effects resulting in noncompliance.
Troops may develop malaria after leaving malarious areas
because of inadequate prophylaxis or poor prophylaxis com-
pliance. Mosquitoes capable of transmitting malaria exist in
the United States, and returning infected troops can trans-
mit the disease to others. Malaria had a major impact in the
Spanish-American War, the Pacific and India–Burma–China
theaters in World War II, and the Vietnam War. Malaria also
afflicted troops in the Korean War, Operation Restore Hope in
Somalia [106], and 2003 operations in Liberia [107]. The U.S.
military has co-developed with GlaxoSmithKline Biologi-
cals a vaccine candidate referred to as RTS,S; trials intended
to lead to licensure of this vaccine for prevention of severe
malaria in children have commenced [108]. The U.S. military
is also currently evaluating alternative approaches (includ-
ing other recombinant protein antigens, viral vectors, naked
DNA, and attenuated sporozoites) to induce potent and long-
lasting immune responses against P. falciparum [109,110].
In 1906, U.S. Army officers CPT P.M. Ashburn and
1LT Charles F. Craig – sent to the Philippines to study
dengue fever (DF) – discovered that DF is caused by a non-
filterable blood-transmitted agent involving neither protozoa
nor bacteria [111]. Dengue viruses have a single-stranded
RNA genome and belong to the genus Flavivirus (as do the
causative agents of yellow fever, Japanese encephalitis, and
West Nile fever). There are four distinct serotypes. Dengue
virus infection (transmitted by Aedes aegypti, A. albopictus,
and A. polynesiensis mosquitoes) may cause an acute painful
febrile illness characterized by headache, muscle/joint pain,
and rash requiring inpatient supportive care. Although this
illness is rarely fatal in adults, dengue is a major cause
of impaired troop readiness. Dengue epidemics adversely
impacted U.S. military operations during the Philippine-
American War, World War II, Vietnam, Somalia, and Haiti. At
present, dengue is an expanding health problem in the trop-
ics and subtropics both in urban and rural areas, and there
have been recent outbreaks in Texas and Hawaii. MIDRP
efforts are focused on the development of a preventive vaccine
using a variety of strategies (live attenuated vaccines, puri-
fied inactivated vaccines, and nucleic acid vaccines) rather
than antiviral treatments for acute infection. Because dengue
hemorrhagic fever – a more severe dengue illness – is associ-
ated with a second dengue infection with a different serotype,
a tetravalent vaccine that protects against all four serotypes
of dengue is ultimately needed [112].
Current U.S. military efforts in prevention of enteric infec-
tions are focused on development of vaccines for the major
causes of diarrhea encountered by deployed U.S. military
personnel—enterotoxigenic E. coli or ETEC (common on a
global basis and also the major cause of travelers’ diarrhea
in civilians), Campylobacter jejuni (common particularly in
Asia), and Shigella (especially Shigella flexneri and S. son-
nei, common particularly in the Middle East during combat
phases of deployment). Over half of U.S. service mem-
bers deployed to the Middle East experience diarrhea due
to occasional compromised hygiene, despite a strong empha-
sis on food and water sanitation by military health authorities.
ETEC is the most common cause of diarrhea in U.S. forces
deploying to many parts of the less developed world and can
cause acute secretory diarrhea, which can result in patient
incapacitation and dehydration.
Shigella are small Gram-negative rod-shaped bacteria that
can cause infections associated with fever and bloody diar-
rhea. The infectious dose is small (10–1000 organisms);
pathogenicity is related to propensity of tissue invasion, but
the organism rarely penetrates beyond the mucosa and rarely
causes bacteremia. Because most isolates of Shigella are
resistant to multiple antimicrobials, successful drug treat-
ment of Shigella infections is likely to become an increasing
challenge.
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C. jejuni is a microaerophilic Gram-negative rod-shaped
bacterium (closely related to Helicobacter pylori). Patients
infected with Campylobacter most commonly present with
fever, diarrhea (watery or bloody), and abdominal pain. The
disease can be severe, but is generally self-limiting with rare
relapses; it is occasionally associated with reactive arthri-
tis and/or Guillain–Barre syndrome. Treatment of C. jejuni
infections, particularly in Southeast Asia, is complicated by
quinolone resistance (noted via stool isolates taken during
joint Thai-U.S. military exercises). The mechanism by which
Campylobacter causes disease is unclear. Development of
a safe and reliable human challenge model is under way
[113].
Potentially fatal hantaviral infections are transmitted to
humans via aerosols of excreta originating from persistently
infected rodents and have impacted U.S. military personnel
deployed to Korea and the former Yugoslavia. Four distinct
hantaviruses cause hemorrhagic fever with renal syndrome
(HFRS): Hantaan virus (found primarily in Asia), Seoul
virus (Asia, Europe, and Scandinavia), Dobrava virus (Balkan
countries and western Russia), and Puumala virus (Scan-
dinavia, Western Europe, and western Russia). Intravenous
ribavirin has been shown to reduce mortality risk of HFRS
only when given early in infection. No FDA-licensed vac-
cines are currently available to prevent this infection, and
the DoD is sponsoring the only known attempt to develop
a vaccine for HFRS in the United States [114]. Newly
emerging hantaviruses that cause potentially fatal hantavirus
pulmonary syndrome (HPS) in the Americas are also a con-
cern. Hantavirus research performed by the U.S. military
could result in medical countermeasures against both HFRS
and HPS.
More than 300 new HIV infections occur annually in
U.S. forces (including new recruits). Service members are at
increased risk of infection when deployed to areas with high
HIV prevalence; the primary risk for deployment-associated
HIV infection is heterosexual encounters. Additionally,
widespread HIV infection in some developing countries
could increase the likelihood of political and financial
instability, which could eventually necessitate peacekeeping
intervention by U.S. military forces. In the mid-1980s, the
U.S. Congress formally recognized the unique threat posed
by HIV and acquired immunodeficiency syndrome (AIDS) to
the operational effectiveness of U.S. military forces, direct-
ing the DoD to establish an HIV/AIDS research program. In
2002, Congress directed MIDRP to cooperate with NIH via
the Division of AIDS at the National Institute of Allergy and
Infectious Diseases (previously focused on B clade infections
found principally within the United States) in the devel-
opment of a globally effective HIV/AIDS vaccine for U.S.
and allied forces protection. The lack of proven success
with traditional antibody-mediated approaches using recom-
binant HIV envelope proteins and the pandemic nature of
HIV justifies the utilization of a variety of other vaccine
approaches including the use of modified vaccinia Ankara
vectors, naked DNA vaccines, and multiclade immunogens.
Aggressive global HIV-1 surveillance and active prevention
programs for the U.S. military and allied militaries around the
world complement vaccine development efforts. The molec-
ular epidemiology of endemic infections is utilized in vaccine
design [115,116].
Vaccines for endemic infectious diseases are important
to global health in addition to the health of the U.S. Armed
Forces. Furthermore, the U.S. military has stationed uni-
formed scientists in the tropics for more than 100 years and
in active overseas laboratories for as long as six decades.
Although development of vaccines is a priority, development
of antimalarial drugs, diagnostic methods, and products to
prevent transmission of diseases by vectors is also ongoing
[117]. In addition, U.S. military scientists contribute to
the development of health and science infrastructure in
these tropical countries, which contributes to political
stability.
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